COMMUNIQUÉS West-GlobeNewswire

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
22/09/2026
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
22/09/2026
First patient marks Polyrizon’s transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with [...]
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
22/09/2026
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 [...]
OneMedNet Expands Commercial Reach Through Multi-Year Resale Agreement with Atropos Health
22/09/2026
MINNEAPOLIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us,” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), [...]
Traferox Technologies Inc. Receives FDA Clearance for the X°Port Heart Preservation System
22/09/2026
MISSISSAUGA, Ontario, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Traferox Technologies, Inc. today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the X°Port ® Heart Preservation System [...]
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
22/09/2026
Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control [...]
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
22/09/2026
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months [...]
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
22/09/2026
Supports Optimi’s planned Phase 2 psilocybin trial in major depressive disorder and Phase 3 MDMA trial in PTSD VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: [...]
Cynet Announces Version 5.0 of its Platform, Unveiling New Cross-Site Dashboard and Enhanced SIEM Capabilities to Maximize Speed, Scale, and Interoperability
22/09/2026
New enhancements deliver major advancements for MSPs, VARs, and end users to manage security environments with existing teams and resources BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Cynet , the only unified, AI-powered [...]
CurePSP Expands Center of Care Network to Europe, Adding Eight New Institutions Worldwide
22/09/2026
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CurePSP announced that its prestigious Center of Care network has expanded beyond North America for the first time since the program's founding in 2017, growing to 44 [...]
New Research Provides Groundbreaking Look Into Brain Processes Behind PANS, PANDAS, Sydenham’s Chorea
22/09/2026
Columbia University researchers identify key inflammatory processes affecting blood-brain barrier in study of post-streptococcal encephalitis NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- For far too long, children and [...]
Sightpath Medical Brings Its Expanded Retina Services to AAO 2026
22/09/2026
Booth 1644, Hall E, shared with technology partner IQity, October 10-12 in New Orleans BLOOMINGTON, Minn., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Sightpath Medical, the nation's leading provider of mobile ophthalmic [...]
SK pharmteco and GEMMABio Expand Rare Disease Manufacturing Collaboration Following Important Spinal Muscular Atrophy (SMA) Clinical Trial Milestone
22/09/2026
First patient dosed marks an important step for the SMA community and highlights a growing rare disease manufacturing partnership, with future GEMMABio programs expected to leverage SK pharmteco’s SKyvec™ viral vector [...]
TETmedical Strengthens Board of Directors with Appointment of Marc Lebel and Patrick McBrayer, Veteran Life Sciences Entrepreneurs and Company Builders
22/09/2026
New Directors Bring Track Record of Founding, Scaling, and Exiting Institutionally-Backed MedTech and Life Sciences Companies as TETmedical Advances Its Pivotal Study FAIR HAVEN, N.J and ITHACA, N.Y., Sept. 22, 2026 ( [...]
SafeSpace Global Secures Up to $11 Million in Financing Capacity to Support Next Phase of Growth
22/09/2026
Multi-year financing framework expands access to growth capital and provides increased financial flexibility as SafeSpace Global KNOXVILLE, Tenn., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: [...]
Bavarian Nordic – Notification of Holding of Treasury Shares
22/09/2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares amounted to 3,965, [...]
Transactions in connection with share buy-back program
22/09/2026
Company announcement no. 36 - 26 22 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
22/09/2026
HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
22/09/2026
At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8 [...]

Pages